MaxCyte News

News

Ticker

MXCT

ISIN

US57777K1060

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

MaxCyte Eulerpool News

MaxCyte Stock News

MaxCyte is being monitored by journalists and investors worldwide. We gather the latest MaxCyte news here.

December 1 ·
Yahoo
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO
November 13 ·
Yahoo
MaxCyte Inc (MXCT) Q3 2025 Earnings Call Highlights: Strategic Moves Amidst Market Challenges
November 7 ·
Yahoo
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Beat Estimates
November 5 ·
Yahoo
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 5 ·
Benzinga
MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance
October 8 ·
Yahoo
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 6 ·
Yahoo
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
September 22 ·
Benzinga
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings
August 11 ·
Yahoo
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio
August 7 ·
SeekingAlpha
MaxCyte, Inc. (MXCT) Q2 2025 Earnings Call Transcript

MaxCyte Stock Press Releases

MaxCyte regularly publishes news on the company's website that are relevant for investors.

MaxCyte News 2026

This page contains all current news, analysis and press releases for MaxCyte stock (MXCT, ISIN: US57777K1060). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at MaxCyte.

MaxCyte Stock

MaxCyte MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products.